Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Dr. Abdalla Abotaleb

Dr. Abdalla Abotaleb

Manager
World Health Organisation
Egypt

Biography

Abdalla Abotalleb is one of the most profound experts in healthcare policy and regulations in the MENA region. His expertise extends from HTA & Reimbursement policies to regulatory and supplies chain strategies in the public sector. He has been involved in the fields of health economics, outcomes research, Health policy reforming and reimbursement policies within the healthcare industry for 15 years, with experience across the pharmaceutical, biologicals and vaccines. And now works for WHO as a project manager at the health care reforming area. Abdalla Abotaleb graduated in the faculty of pharmacy then obtained a post-graduate in health economics followed by a Ph.D. in Health Economics & Policy form York University. He also has a degree in Project management professional (PMP), Pharm. D certificate and a Master of business administration (MBA).

Research Interest

Selecting the right patient for the right treatment with the efficient cost is the main goal for an effective health system. When Lung cancer comes at top 20 cause of death in and third rank in mortality rates among all cancer types in Egypt due to previous facts and high population for Egypt which categorized as low income country which lead to Increase economic burden on health care system and creating a need for managing and minimizing that burden plus how policy maker enhance patient’s outcomes (clinical aspect–economic aspect–quality of life aspect). The objective of this study is policy analysis for Health care policymaker in oncology for diversion of concept for reimbursement system from price into economic value and it is consequences on patient outcomes and health system resources. By analyzing Reimbursement case for Oral Vinorelbine at Non-Small-Cell Lung Cancer